LONDON, Sept. 28, 2015 /PRNewswire/ -- Smith & Nephew (NYSE:SNN;LSE:SN), the global, medical technology business, today announced the launch of its new NASASTENT Dissolvable Nasal Dressing, a structural intranasal splint used to minimize bleeding and prevent post-op adhesions after sinus surgery.
Made from a plant-based material known as CarboxyMethyl Cellulose (CMC), the NASASTENT dressing can be easily customized by simply trimming it to fit the size needs of each patient and offers tapered edges for ease of placement into the nasal cavity. Once in place, the soft dressing quickly regains its shape as it conforms to the patient’s anatomy; providing sufficient pressure to minimize bleeding and hold the surrounding soft tissues in place as they heal. Recent testing shows that the NASASTENT dressing’s compressive strength is six-times greater than its leading competitor and provides significantly higher tissue separation force over a variety of simulated nasal cavity gaps ranging from 7 to 10mm.i
Also, unlike other structural dressings which break down into fragments that must be later removed by a physician, the CMC used in the NASASTENT dressing converts into a hydrocolloidal gel after absorbing sufficient nasal fluid and simply drains from the cavity as part of the natural outflow. CMC has a well-documented clinical history with over two decades of use in the pharmaceuticalii and medical deviceiii industries. The NASASTENT dressing is capable of absorbing up to 16-times its dry weight in fluid and does not require any special storage conditionsiv.
“Smith & Nephew is committed to innovation that improves both the patient and the physician experience and is proud to offer pioneering technologies such as NASASTENT within our leading specialist ENT surgical portfolio,” said Mira Sahney, General Manager for ENT and Gynecology.
Surgeons attending the annual American Academy of Otolaryngology Surgeons (AAO) meeting this week in Dallas will be able to learn more about the NASASTENT Dissolvable Nasal Dressing at the Smith & Nephew booth #1721.
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 14,000 employees and a presence in more than 100 countries. Annual sales in 2014 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).
For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.
Trademark of Smith & Nephew. Registered US Patent and Trademark Office.
i P/N 67244
ii The use of micronized cellulose disintegrants as insoluble swellable matrices for sustained-release tablets. Nakagami H, Nada M. Drug Des Deliv. 1991 Jul;7(4):321-32.
iii Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study. Seprafilm Adhesion Study Group. Diamond MP. Fertil Steril. 1996 Dec; 66(6):904-10.
iv P/N 67130
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-customizable-nasastent-nasal-dressing-from-smith--nephew-designed-to-dissolve-completely-300149501.html
SOURCE Smith & Nephew
Help employers find you! Check out all the jobs and post your resume.
